



Disrupting Dialysis:

The First Fully Implantable Renal Assist Device Ending the \$100B "External Dialysis" era.

Replace tethered dialysis with a fully implantable system that restores patient autonomy and slashes healthcare costs

- Dialysis consumes 7% of the Medicare budget
- Costs \$100K per patient annually
- Offers zero patient autonomy

It is a 60-year-old model ripe for disruption

The Unfair Advantage: US Medicare Mandate

Medicare covers all dialysis treatments for ESRD patient, regardless of age
\$50B+ annual federal pool

The Solution: "Safe-by-Design" Tech

The First Continuous
Fully Implantable
Alternative to Dialysis



- **Minimized Risk:** Venous-access only, no high-risk arterial connections
- **Physiological Integration:** Direct evacuation to the bladder, mimicking natural kidney function
- **AI-Precision:** ML-driven filtration for real-time, personalized adaptation

Regulatory Roadmap: Targeting FDA De Novo classification with Breakthrough Designation

**Supported by the Israel Innovation Authority.
Granted US Patents and pending IP in Japan/EU**

The Business Model: Anchor & Recurring

Anchor: Device pricing anchored to the \$100K annual dialysis cost (Immediate Payer ROI)
Recurring: Long-term Remote Patient Management (RPM) revenue streams

The Team



Nava Barit Ben David
CEO, Co-founder



Dr. Ehud Jacobzon, MD
CSO, Co-founder



Yaniv Ben Haim
Co-founder, Board member



**Shaare Zedek
Scientific, Madait**

Investment Opportunity:

Selectively opening Pre-Seed round to accelerate POC animal trials (H1 2026)



nava@renalyte.com



+972526045224



[Renalyte in a 1 minute clip](#)